Anecortave
Alternative Names: AL 3789; Anacortave; Anecortave acetate; Anecortave sodium; RetaaneLatest Information Update: 15 Apr 2019
At a glance
- Originator Alcon
- Developer Alcon; Novartis
- Class Eye disorder therapies; Pregnadienediols; Small molecules
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Age-related macular degeneration
- Discontinued Eye disorders; Glaucoma; Hereditary haemorrhagic telangiectasia
Most Recent Events
- 09 Apr 2019 Novartis completed the spin-off of Alcon eye care devices business
- 26 Aug 2010 Alcon has been acquired by Novartis
- 03 Jul 2009 Discontinued - Phase-II/III for Glaucoma in USA (Ophthalmic)